Holen Sie sich die Stockscreener-App
40.66
3.88%
1.52
Handel nachbörslich:
40.90
0.24
+0.59%
Schlusskurs vom Vortag:
$39.14
Offen:
$38.66
24-Stunden-Volumen:
1.01M
Relative Volume:
2.24
Marktkapitalisierung:
$2.63B
Einnahmen:
$87.56M
Nettoeinkommen (Verlust:
$-167.47M
KGV:
-14.73
EPS:
-2.76
Netto-Cashflow:
$-148.20M
1W Leistung:
-3.49%
1M Leistung:
-7.70%
6M Leistung:
+30.03%
1J Leistung:
+65.96%
1-Tages-Spanne:
$38.24
$40.77
1-Wochen-Bereich:
$37.09
$44.17
52-Wochen-Spanne:
$22.35
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
40.66 | 2.63B | 87.56M | -167.47M | -148.20M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
HighTower Advisors LLC Takes $494,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
BMO Capital Initiates Coverage of Kymera Therapeutics (KYMR) with Market Perform Recommendation - MSN
BTIG Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation - MSN
State Street Corp Has $81.79 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Verition Fund Management LLC - Defense World
(KYMR) Investment Analysis - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) Now Covered by BTIG Research - MarketBeat
Two Sigma Advisers LP Lowers Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Wellington Management Group LLP Has $218.59 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Research Coverage Started at BMO Capital Markets - Defense World
Kymera: Protein Degradation Could Drive Dupixent-Like Value (NASDAQ:KYMR) - Seeking Alpha
BMO Capital Markets Initiates Coverage on Kymera Therapeutics (NASDAQ:KYMR) - MarketBeat
Thrivent Financial for Lutherans Takes $313,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
The Manufacturers Life Insurance Company Has $6.07 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
BMO sets Kymera Therapeutics target at $55, rates Market Perform By Investing.com - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is Redmile Group LLC's 5th Largest Position - MarketBeat
(KYMR) Long Term Investment Analysis - Stock Traders Daily
Bamco Inc. NY Invests $1.18 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Erste Asset Management GmbH Acquires New Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Kymera therapeutics director Pamela Esposito sells shares worth $122,500 By Investing.com - Investing.com Nigeria
Kymera therapeutics director Pamela Esposito sells shares worth $122,500 - Investing.com India
12,743 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Purchased by HighVista Strategies LLC - MarketBeat
Cinctive Capital Management LP Acquires Shares of 56,801 Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Kymera Therapeutics shares rating upgraded on positive outlook By Investing.com - Investing.com Canada
Kymera Therapeutics (NASDAQ:KYMR) Upgraded by Wells Fargo & Company to Overweight Rating - Defense World
Wells Fargo Upgrades Kymera Therapeutics (KYMR) - MSN
Wells Fargo sees this biotech stock rallying 75% in its bull case - Head Topics
Fred Alger Management LLC Invests $859,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Fmr LLC Boosts Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Intech Investment Management LLC Invests $650,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Intech Investment Management LLC Makes New $650,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Bought by Eventide Asset Management LLC - MarketBeat
14,378 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Bought by Natixis Advisors LLC - MarketBeat
Natixis Advisors LLC Purchases Shares of 14,378 Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics announces proposed underwritten offering - MSN
Kymera Therapeutics to Participate in Upcoming December Investor Conferences - The Manila Times
Kymera Therapeutics to Present at Major Healthcare Investment Conferences in December | KYMR Stock News - StockTitan
Massachusetts Financial Services Co. MA Purchases 47,507 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
(KYMR) Trading Report - Stock Traders Daily
Jennison Associates LLC Purchases 368,394 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Stephens Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Stephens - MarketBeat
US Bancorp DE Sells 651 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7%Here's What Happened - MarketBeat
Avoro Capital Advisors LLC Expands Stake in Kymera Therapeutics Inc - GuruFocus.com
Long Term Trading Analysis for (KYMR) - Stock Traders Daily
FMR LLC Bolsters Stake in Kymera Therapeutics Inc - GuruFocus.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $51.21 Average Price Target from Analysts - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $49.00 at Morgan Stanley - Defense World
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $51.21 - MarketBeat
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):